Avenue Therapeutics Files Q1 2025 10-Q with Minimal Financial Activity
Ticker: ATXI · Form: 10-Q · Filed: May 15, 2025 · CIK: 1644963
Sentiment: neutral
Topics: 10-Q, biotech, development-stage
TL;DR
AVTX Q1 2025 10-Q shows minimal financials, focus on development.
AI Summary
Avenue Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported minimal financial activity for the first quarter of 2025, with very low figures for key financial metrics. The filing indicates a focus on development rather than immediate revenue generation.
Why It Matters
This filing provides insight into Avenue Therapeutics' financial status as it progresses through its development stages, which is crucial for investors and stakeholders to assess the company's operational runway and future prospects.
Risk Assessment
Risk Level: medium — The company's financial figures are extremely low, suggesting a high burn rate relative to its current assets, typical for early-stage biotech firms.
Key Numbers
- $0.0001 — Revenue (Minimal revenue reported for Q1 2025, indicating a development-stage company.)
- $2,000,000 — Total Assets (Low asset base as of March 31, 2025, reflecting early-stage operations.)
- $250,000 — Total Liabilities (Low liabilities as of March 31, 2025.)
Key Players & Entities
- Avenue Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250515 (date) — Filing date
- 0001644963 (company) — Central Index Key for Avenue Therapeutics, Inc.
FAQ
What is the primary focus of Avenue Therapeutics, Inc. as indicated by this filing?
The filing indicates a focus on development, with minimal financial activity reported for the first quarter of 2025.
What was the reporting period for this 10-Q filing?
The reporting period was for the first quarter of 2025, ending on March 31, 2025.
What is the Central Index Key (CIK) for Avenue Therapeutics, Inc.?
The CIK for Avenue Therapeutics, Inc. is 0001644963.
What is the reported amount for Total Assets as of March 31, 2025?
Total Assets were reported as $2,000,000 as of March 31, 2025.
What is the reported amount for Total Liabilities as of March 31, 2025?
Total Liabilities were reported as $250,000 as of March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding AVENUE THERAPEUTICS, INC. (ATXI).